Results are expressed as mean _+ SD. a p < 0.05; b N.S. In both groups one patient with longer existing diabetes was included (40 years) abolic control without complications. It is not known whether this phenomenon is a primary or secondary effect of these complications. However, we also studied three siblings of one of our patients with microangiopathic complications, all of whom had Type i diabetes without complications. Elevated levels of fi TG and PF 4 were found suggesting a primary defect of platelet activation in vivo. These higher levels of both fi TG and PF 4 warrant further investigation of the possible effect of inhibitors of platelet 
Subcutaneous Degradation of Insulin
Dear Sir, A considerable degree of degradation of injected insulin has been demonstrated in pigs [1] and man [2] . Others have published case histories of insulin-dependent diabetics being resistant to subcutaneously injected insulin, but sensitive to intravenously administered insulin [3, 4] . Is the subcutaneous degradation of insulin really a common clinical problem?
To study the subcutaneous degradation of insulin, highly purified porcine ~25I-NPH-insulin was injected into six pigs. Each pig was given five injections of 8 units (0.2 ml) nSI-NPH-insulin 5 mm beneath the skin. Between one, 180, and 300 min after injection, subcutaneous tissue around the injection site was removed and insulin extracted with 20% CH3COOH , 8 mol/1 urea (unpublished data). No radioactivity was left at the injection site or in the extracted tissue. Radioactivity and immunoreactive insulin in extracts of biopsies from the injection site were determined and correlated as seen in Figure 1 . A good correlation was found, indicating only minor accumulation of insulin degradation products in the subcutaneous tissue. In another study a good correlation has been found between disappearance of radioactivity from subcutaneously injected labelled insulin and appearance of immunoreactive insulin in human plasma [5] .
Furthermore, insulin requirement per 24 h during conventional subcutaneous insulin injection treatment was compared with insulin requirement during intravenous insulin infusion in 57 patients with insulin dependent diabetes. Injection treatment was defined as the mean daily insulin dose injected during the last year. All patients were treated with a mixture of highly purified porcine NPH insulin and soluble insulin twice daily. Thirty-two patients were then converted to treatment with an intravenous open-loop system as described previously [6] , and 25 patients converted to intravenous insulin treatment with the Biostator (closed-loop) [7] . Capillary blood glucose was nearly normalized by both methods [7] . A significant correlation was found between the subcutaneously injected and the intravenously infused dose of insulin (Fig. 2) , indicating only minimal loss of insulin by subcutaneous degradation. Also, the insulin dose before and after converting 18 insulin dependent patients from subcutaneous insulin injection therapy with NPH insulin to subcutaneous infusion with soluble insulin (and near-normalization of glucose) was significantly correlated (Fig. 3) , indicating no difference in degradation between NPH and soluble insulin.
Aprotinin (Trasylol) has been postulated to inhibit subcutaneous degradation of insulin, resulting in increased insulin absorption [2] . Therefore, we studied the increase of venous plasma insulin in seven fasting non-obese insulin independent diabetics after subcutaneous injection of 0.05 units/kg highly purified porcine soluble insulin in 0.5 ml sodium chloride with and without aprotinin 10,000 Kallikrein-inactivator units. No difference of plasma insulin was found (Fig. 4 ) indicating no effect of aprotinin on absorption of insulin.
Thus, subcutaneous insulin degradation does not seem to be a major clinical problem.
Yours sincerely, T. Deckert, B. Hansen, T. Lauritzen and J. Sandahl Christiansen tiansen
